TrialThe Lancet. Respiratory medicine2018

Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study.

Luana Calabrò et al.PubMed ↗Publisher ↗

No numbers read from the abstract.